| xu, jianmin |
NCT05540951: VIC Regimen Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Advanced Colorectal Cancer |
|
|
| Recruiting | 3 | 78 | RoW | VIC, Bevacizumab Plus Chemotherapy | Fudan University | Colorectal Cancer | 08/22 | 12/22 | | |
PIDUC, NCT04912258: Preoperative Irinotecan Drug-eluting Beads for Patients With Unresectable Colorectal Liver Metastasis |
|
|
| Not yet recruiting | 3 | 80 | RoW | Trans arterial chemoembolization with Irinotecan Drug-eluting Beads, Irinotecan Drug-eluting Beads | Fudan University | Colorectal Cancer, Liver Metastases | 12/22 | 06/23 | | |
NCT04687631: Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases |
|
|
| Recruiting | 3 | 508 | RoW | mFOLFOXIRI plus Cetuximab, mFOLFOXIRI Plus Bevacizumab | Fudan University | Colorectal Cancer, Liver Metastases | 03/25 | 09/27 | | |
BECOME2, NCT04781270: mFOLFOXIRI+Bev vs. mFOLFOX6+Bev for RAS Mutant Unresectable Colorectal Liver-limited Metastases |
|
|
| Recruiting | 3 | 308 | RoW | mFOLFOXIRI regimen, mFOLFOX regimen, Bevacizumab | Fudan University | Colorectal Carcinoma, Liver Metastases | 03/24 | 03/26 | | |
NCT05948072: Cetuximab+mFOLFOX6 VS. mFOLFOX6 Alone in RAS/BRAF Wild Type Patients With High-Risk Resectable CRLM |
|
|
| Not yet recruiting | 3 | 250 | RoW | mFOLFOX6 + Cetuximab, mFOLFOX 6 | Fudan University | Colorectal Cancer, Liver Metastases | 07/26 | 07/26 | | |
NCT05086614: Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer |
|
|
| Recruiting | 3 | 2500 | RoW | Thymosin Alpha1, Thymalfasin | Fudan University | Stage II Colorectal Cancer, Stage III Colorectal Cancer | 03/27 | 03/27 | | |
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer |
|
|
| Recruiting | 3 | 711 | Europe, Canada, Japan, US, RoW | Dostarlimab, CAPEOX, FOLFOX | GlaxoSmithKline | Colonic Neoplasms, Neoplasms, Colon | 12/28 | 12/30 | | |
NCT06218810: Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer |
|
|
| Recruiting | 2 | 53 | RoW | Cadonilimab + bevacizumab + FOLFOX | Fudan University | Metastatic Colorectal Cancer, Microsatellite Stable Colorectal Carcinoma, RAS Mutation, Cadonilimab | 12/25 | 12/26 | | |
| Recruiting | 2 | 73 | RoW | SHR-1701ï¼›Capecitabineï¼›Oxaliplatin | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Locally Advanced Rectal Cancer | 07/24 | 10/26 | | |
| Recruiting | 2 | 23 | RoW | Dostarlimab, GSK4057190A, TSR-042 | GlaxoSmithKline | Neoplasms, Rectal | 12/28 | 03/31 | | |
NCT05555901: The Efficacy and Safety of Fruquintinib Plus Chemotherapy as Second-line Treatment in Metastatic Colorectal Cancer |
|
|
| Recruiting | 2 | 116 | RoW | Fruquintinib+ chemotherapy, Bevacizumab+ chemotherapy | Fudan University | Metastatic Colorectal Cancer | 09/25 | 09/25 | | |
NCT06221423: Fruquintinib Combined With TAS-102 in Refractory Metastatic Colorectal Cancer |
|
|
| Recruiting | N/A | 20 | RoW | Fruquintinib Combined With TAS-102 | Fudan University | Colorectal Cancer, Metastatic Colorectal Cancer, Refractory Colorectal Carcinoma | 05/24 | 05/24 | | |
NCT06202417: Fruquintinib in Refractory Metastatic Colorectal Cancer: A Real-world Study |
|
|
| Completed | N/A | 520 | RoW | Fruquintinib, PD1 antibodies, chemotherapy drugs | Fudan University | Colorectal Cancer, Refractory Colorectal Cancer, Metastatic Colorectal Cancer | 06/22 | 12/23 | | |
NCT06027775: Chemotherapy Alone Versus Chemotherapy Plus Targeted Therapy as Adjuvant Therapy for Initially Unresectable Colorectal Cancer Liver Metastases |
|
|
| Completed | N/A | 198 | NA | Targeted agent | Fudan University | Colorectal Cancer Metastatic | 01/23 | 01/23 | | |
NCT06023173: Deep Radiomics-based Fusion Model Predicting Bevacizumab Treatment Response and Outcome in Patients With Colorectal Liver Metastases |
|
|
| Completed | N/A | 307 | RoW | Deep radiomics-based fusion model, deep learning model | Fudan University | The Patients With CRLM Who Benefit More From Bevacizumab | 01/23 | 01/23 | | |
| Active, not recruiting | N/A | 1240 | RoW | Robot-assisted resection, Laparoscopic resection | Fudan University | Rectal Carcinoma | 12/23 | 12/23 | | |
DEBIRI, NCT06177288: Combined With Chemotherapy and Bevacizumab in the Treatment of Unresectable Colorectal Cancer Liver Metastases |
|
|
| Not yet recruiting | N/A | 39 | RoW | DEBIRI Combined With Chemotherapy and Bevacizumab | Fudan University | Colorectal Neoplasms | 01/25 | 05/25 | | |
NCT05873972: Multimodal Model for Efficacy Prediction Cetuximab in Colorectal Cancer Liver Metastasis Patient |
|
|
| Not yet recruiting | N/A | 100 | RoW | Cetuximab | Fudan University | Colorectal Cancer Liver Metastases | 06/24 | 12/24 | | |
NCT05354674: Multimodal Deep Learning Signature for Evaluation of Response to Bevacizumab in Patient With Colorectal Cancer Liver Metastasis |
|
|
| Not yet recruiting | N/A | 302 | RoW | Bevacizumab | Fudan University | Colorectal Cancer, Liver Metastases | 07/25 | 07/28 | | |
NCT05881746: Anatomical Resection VS. Nonanatomical Resection for Colorectal Liver Metastases With Gene Mutation or Right-sidedness |
|
|
| Not yet recruiting | N/A | 176 | RoW | anatomical liver resection, nonanatomical liver resection | Fudan University | Colorectal Carcinoma, Liver Metastases | 07/26 | 07/28 | | |
METHOD-3, NCT05638243: Evaluation of a Model for the Early Diagnosis of Colorectal Cancer by the Detection of 5-hydroxymethylcytosine (5-hmC) in Plasma Cell-free DNA to the Community Colorectal Cancer Screening Program |
|
|
| Recruiting | N/A | 10000 | RoW | | Fudan University | Colorectal Cancer, Colorectal Neoplasms | 02/25 | 09/25 | | |
